Cytek Net Debt from 2010 to 2026

CTKB Stock

USD 4.47 0.03 0.67%

Cytek Biosciences' Net Debt is decreasing over the years with slightly volatile fluctuation. Net Debt is expected to dwindle to about -77.2 M. Net Debt is the total debt of Cytek Biosciences minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2020-03-31

Previous Quarter

-51.8 M

Current Value

-58.1 M

Quarterly Volatility

114.9 M

Covid

Interest Hikes

Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 386.4 K, Net Interest Income of 12.5 M or Interest Income of 12.5 M, as well as many indicators such as Price To Sales Ratio of 4.62, Dividend Yield of 0.0 or PTB Ratio of 2.02. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.

Build AI portfolio with Cytek Stock

Check out the analysis of Cytek Biosciences Correlation against competitors.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Analyzing Cytek Biosciences's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.

Latest Cytek Biosciences' Net Debt Growth Pattern

Below is the plot of the Net Debt of Cytek Biosciences over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Cytek Biosciences' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Cytek Net Debt Regression Statistics

	Arithmetic Mean	(87,788,441)
	Coefficient Of Variation	(112.64)
	Mean Deviation	71,481,557
	Median	(30,122,000)
	Standard Deviation	98,888,900
	Sample Variance	9779T
	Range	334.5M
	R-Value	(0.48)
	Mean Square Error	7987.7T
	R-Squared	0.23
	Significance	0.05
	Slope	(9,477,713)
	Total Sum of Squares	156464.2T

Cytek Net Debt History

	2026	-77.2 M
	2025	-73.5 M
	2024	-81.7 M
	2023	-153.2 M
	2022	-278.5 M
	2021	-364.6 M
	2020	-162.5 M

Other Fundumenentals of Cytek Biosciences

Net Debt To E B I T D A

Cytek Biosciences Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt	Capital Surpluse	Deferred Long Term Liab	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.97	0.86	-0.67	0.61	0.85	0.93	0.95	-0.29	0.99	1.0	0.99	0.99	-0.02	0.81	0.99	0.93	0.04	0.7	0.87	-0.72	-0.41
Total Stockholder Equity	0.99		0.98	0.83	-0.67	0.58	0.83	0.92	0.96	-0.43	1.0	0.98	1.0	0.98	0.08	0.8	1.0	0.92	-0.01	0.68	0.85	-0.7	-0.38
Net Tangible Assets	0.97	0.98		0.91	-0.6	0.49	0.82	0.91	0.94	-0.43	0.98	0.97	0.98	0.96	0.03	0.87	0.98	0.96	0.12	0.74	0.86	-0.76	-0.55
Current Deferred Revenue	0.86	0.83	0.91		-0.23	0.16	0.84	0.92	0.9	-0.29	0.84	0.82	0.85	0.79	-0.16	0.98	0.85	0.96	0.46	0.87	0.93	-0.94	-0.71
Net Debt	-0.67	-0.67	-0.6	-0.23		-0.94	-0.33	-0.37	-0.46	0.17	-0.67	-0.73	-0.65	-0.77	-0.21	-0.18	-0.65	-0.42	0.55	-0.08	-0.26	0.01	-0.04
Retained Earnings	0.61	0.58	0.49	0.16	-0.94		0.31	0.35	0.39	0.11	0.58	0.66	0.55	0.69	-0.05	0.11	0.55	0.36	-0.59	-0.01	0.25	0.05	0.2
Accounts Payable	0.85	0.83	0.82	0.84	-0.33	0.31		0.91	0.86	-0.2	0.83	0.83	0.84	0.8	-0.06	0.75	0.84	0.86	0.41	0.83	0.91	-0.83	-0.46
Net Receivables	0.93	0.92	0.91	0.92	-0.37	0.35	0.91		0.98	-0.32	0.92	0.89	0.93	0.86	-0.14	0.89	0.93	0.95	0.22	0.8	0.98	-0.86	-0.42
Good Will	0.95	0.96	0.94	0.9	-0.46	0.39	0.86	0.98		-0.39	0.96	0.92	0.97	0.9	0.02	0.9	0.97	0.93	0.16	0.76	0.92	-0.85	-0.4
Total Liab	-0.29	-0.43	-0.43	-0.29	0.17	0.11	-0.2	-0.32	-0.39		-0.43	-0.29	-0.44	-0.29	-0.56	-0.29	-0.44	-0.32	0.08	-0.24	-0.27	0.22	0.18
Net Invested Capital	0.99	1.0	0.98	0.84	-0.67	0.58	0.83	0.92	0.96	-0.43		0.98	1.0	0.98	0.08	0.8	1.0	0.92	0.0	0.68	0.86	-0.7	-0.38
Total Current Assets	1.0	0.98	0.97	0.82	-0.73	0.66	0.83	0.89	0.92	-0.29	0.98		0.98	1.0	0.01	0.77	0.98	0.91	0.0	0.67	0.83	-0.67	-0.4
Capital Stock	0.99	1.0	0.98	0.85	-0.65	0.55	0.84	0.93	0.97	-0.44	1.0	0.98		0.97	0.06	0.81	1.0	0.93	0.01	0.7	0.87	-0.72	-0.39
Net Working Capital	0.99	0.98	0.96	0.79	-0.77	0.69	0.8	0.86	0.9	-0.29	0.98	1.0	0.97		0.03	0.74	0.97	0.89	-0.04	0.64	0.8	-0.63	-0.39
Short Term Debt	-0.02	0.08	0.03	-0.16	-0.21	-0.05	-0.06	-0.14	0.02	-0.56	0.08	0.01	0.06	0.03		-0.14	0.06	-0.2	-0.03	-0.14	-0.27	0.06	0.11
Intangible Assets	0.81	0.8	0.87	0.98	-0.18	0.11	0.75	0.89	0.9	-0.29	0.8	0.77	0.81	0.74	-0.14		0.81	0.92	0.42	0.82	0.88	-0.94	-0.66
Common Stock	0.99	1.0	0.98	0.85	-0.65	0.55	0.84	0.93	0.97	-0.44	1.0	0.98	1.0	0.97	0.06	0.81		0.93	0.01	0.7	0.87	-0.72	-0.39
Property Plant Equipment	0.93	0.92	0.96	0.96	-0.42	0.36	0.86	0.95	0.93	-0.32	0.92	0.91	0.93	0.89	-0.2	0.92	0.93		0.25	0.82	0.95	-0.83	-0.61
Short Long Term Debt	0.04	-0.01	0.12	0.46	0.55	-0.59	0.41	0.22	0.16	0.08	0.0	0.0	0.01	-0.04	-0.03	0.42	0.01	0.25		0.58	0.31	-0.64	-0.67
Capital Surpluse	0.7	0.68	0.74	0.87	-0.08	-0.01	0.83	0.8	0.76	-0.24	0.68	0.67	0.7	0.64	-0.14	0.82	0.7	0.82	0.58		0.87	-0.85	-0.78
Deferred Long Term Liab	0.87	0.85	0.86	0.93	-0.26	0.25	0.91	0.98	0.92	-0.27	0.86	0.83	0.87	0.8	-0.27	0.88	0.87	0.95	0.31	0.87		-0.86	-0.52
Long Term Debt	-0.72	-0.7	-0.76	-0.94	0.01	0.05	-0.83	-0.86	-0.85	0.22	-0.7	-0.67	-0.72	-0.63	0.06	-0.94	-0.72	-0.83	-0.64	-0.85	-0.86		0.63
Long Term Debt Total	-0.41	-0.38	-0.55	-0.71	-0.04	0.2	-0.46	-0.42	-0.4	0.18	-0.38	-0.4	-0.39	-0.39	0.11	-0.66	-0.39	-0.61	-0.67	-0.78	-0.52	0.63

Click cells to compare fundamentals

About Cytek Biosciences Financial Statements

Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' Net Debt, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-73.5 M	-77.2 M
Net Debt To EBITDA	7.33	7.70

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:

How To Invest In Cytek

Details

Is Cytek Stock a good investment?

Details

What is Cytek Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Cytek Biosciences Correlation against competitors.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Quarterly Earnings Growth

0.735

Earnings Share

(0.11)

Revenue Per Share

1.538

Quarterly Revenue Growth

0.015

Return On Assets

(0.04)

Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.

It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Cytek Net Debt from 2010 to 2026

Latest Cytek Biosciences' Net Debt Growth Pattern

Cytek Net Debt Regression Statistics

Cytek Net Debt History

Other Fundumenentals of Cytek Biosciences

Cytek Biosciences Net Debt component correlations

About Cytek Biosciences Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY